Trial results

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT05869903 on ClinicalTrials.gov · last registry update 2026-08-14

An unusually large phase 3: 3,127 participants, more than double the 424 typical for the stage. The sponsor logged completion for 25 July 2025. Primary outcome, as filed: Percent Change From Baseline in Body Weight (Primary Treatment Period). orforglipron is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

orforglipron

Foundayo

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

3,127

Started

2023-06-05

Primary completion

2025-07-25 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change From Baseline in Body Weight (Primary Treatment Period)

Conditions studied

Obesity · Overweight · Overweight or Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.